Gianmarco Putti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gianmarco Putti has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Blasi
Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy
3 shared publications - Andrea Gramegna
Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
2 shared publications Alessandra Mariani
Healthcare Professions Department, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
1 shared publicationAndrea Gramegna
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
1 shared publicationChiara Macchi
Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy
1 shared publication- Chiara Premuda
Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-13
Tackling Neutrophilic Inflammation in Bronchiectasis: From Macrolides to Cathepsin C Inhibitors
Neutrophilic airway inflammation is a key pathogenic driver of bronchiectasis, sustaining a vicious cycle of infection, mucus obstruction, recurrent exacerbations and progressive airway damage. The growing knowledge on the neutrophilic bronchiectasis endotype has led to increasing interest in host-directed approaches targeting neutrophilic mediators. Long-term macrolide therapy currently represents the reference anti-inflammatory treatment for patients with bronchiectasis at high risk of exacerbations and is supported by randomized controlled trials and extensive clinical experience. However, its use is limited by antimicrobial resistance, drug–to-drug interactions, safety concerns in selected populations and uncertainty regarding optimal dosing and duration. More recently, inhibition of Cathepsin C (CatC), an upstream regulator of neutrophil serine protease activation, has emerged as a novel therapeutic strategy aimed at reducing protease-driven airway injury. This manuscript presents a focused review of the literature that critically examines and compares long-term macrolides and CatC inhibitors with respect to their mechanisms of action, clinical evidence, safety profiles and potential roles within future treatment algorithms. We summarize data from Phase II and III trials of CatC inhibitors, particularly brensocatib, highlighting their effects on exacerbation risk, lung function trajectories and biomarkers of neutrophilic inflammation. We also discuss the limitations of the current evidence base, including restricted trial populations, limited long-term data and the lack of validated biomarkers to guide treatment selection in clinical practice. Finally, we discuss future perspectives for integrating these therapies into individualized, biomarker-informed management of bronchiectasis. Together, these developments support a shift towards more mechanism-based and personalized anti-inflammatory treatment strategies in bronchiectasis, in which treatment selection is guided by underlying inflammatory pathways. This review aims to translate current clinical evidence into practical considerations for patient selection and future therapeutic positioning, thereby helping bridge the gap between research and clinical implementation.
- 1 April 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-13
Open AccessTackling Neutrophilic Inflammation in Bronchiectasis: From Macrolides to Cathepsin C Inhibitors
Neutrophilic airway inflammation is a key pathogenic driver of bronchiectasis, sustaining a vicious cycle of infection, mucus obstruction, recurrent exacerbations and progressive airway damage. The growing knowledge on the neutrophilic bronchiectasis endotype has led to increasing interest in host-directed approaches targeting neutrophilic mediators. Long-term macrolide therapy currently represents the reference anti-inflammatory treatment for patients with bronchiectasis at high risk of exacerbations and is supported by randomized controlled trials and extensive clinical experience. However, its use is limited by antimicrobial resistance, drug–to-drug interactions, safety concerns in selected populations and uncertainty regarding optimal dosing and duration. More recently, inhibition of Cathepsin C (CatC), an upstream regulator of neutrophil serine protease activation, has emerged as a novel therapeutic strategy aimed at reducing protease-driven airway injury. This manuscript presents a focused review of the literature that critically examines and compares long-term macrolides and CatC inhibitors with respect to their mechanisms of action, clinical evidence, safety profiles and potential roles within future treatment algorithms. We summarize data from Phase II and III trials of CatC inhibitors, particularly brensocatib, highlighting their effects on exacerbation risk, lung function trajectories and biomarkers of neutrophilic inflammation. We also discuss the limitations of the current evidence base, including restricted trial populations, limited long-term data and the lack of validated biomarkers to guide treatment selection in clinical practice. Finally, we discuss future perspectives for integrating these therapies into individualized, biomarker-informed management of bronchiectasis. Together, these developments support a shift towards more mechanism-based and personalized anti-inflammatory treatment strategies in bronchiectasis, in which treatment selection is guided by underlying inflammatory pathways. This review aims to translate current clinical evidence into practical considerations for patient selection and future therapeutic positioning, thereby helping bridge the gap between research and clinical implementation.
- 16 October 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (1) , 63-69
Limited impact of Elexacaftor/Tezacaftor/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training
- 16 October 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (1) , 63-69
Limited impact of Elexacaftor/Tezacaftor/Ivacaftor on CPET outcomes in an Italian cohort of people with Cystic Fibrosis: reinforcing the essential role of exercise training
- Open Access
- 6 December 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (1) , 53-56
Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor/tezacaftor/ivacaftor therapy
- 6 December 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (1) , 53-56
Open AccessCardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor/tezacaftor/ivacaftor therapy